Ph.D., Chief Executive Officer, Karius
Dr. Kertesz co-founded Karius in 2014 to bring the novel pathogen detection technology he and colleagues developed at Stanford closer to the bedside. Based in Redwood City, California, Karius now provides a Next-Generation Sequencing based test that is able to identify over a thousand pathogens from a single blood draw. Prior to founding Karius, Dr. Kertesz was the CEO and co-founder of Moleculo, a long-reads DNA sequencing company, which was acquired by Illumina in late 2012. Dr. Kertesz earned an MS in computer science from Tel Aviv University and a PhD in computational biology from the Weizmann Institute of Science. He went on to join the Quake lab at Stanford University for his postdoctoral research in bioengineering, where he developed methods for investigating the genetic diversity of human viruses.
Genomics for Infectious Disease: Liquid Biopsy for Pathogen Detection
Discover a novel NGS infectious disease diagnostic that detects microbial cell-free DNA (cfDNA) in plasma from more than a thousand pathogens including bacteria, DNA viruses, fungi and protozoa in one day. Hear patient cases and clinical data on the Karius comprehensive liquid biopsy for pathogen detection (incl. sepsis, invasive fungal infections and immunocompromised patients).